Neuronetics (STIM) has just put fresh numbers on the table for Q1 2026, and recent filings show quarterly revenue at US$41.8 million in Q4 2025 with a basic EPS loss of US$0.10, alongside trailing twelve month revenue of US$149.2 million and a basic EPS loss of US$0.59. Over recent quarters, the company has seen revenue move from US$18.5 million in Q3 2024 to US$22.5 million in Q4 2024 and then to US$42.8 million in Q4 2025, while quarterly basic EPS losses shifted from US$0.44 to US$0.35 and then to US$0.10. This sets the stage for investors to weigh top-line momentum against still negative margins.

See our full analysis for Neuronetics.

With the headline figures in place, the next step is to see how these results line up with the most common narratives around Neuronetics, and where the data pushes back against those stories.

Gross margin pressure from clinic mix

• Net income loss for Q4 2025 was US$7.2 million on US$41.8 million of revenue, compared with a US$12.7 million loss on US$32.0 million of revenue in Q1 2025, reflecting the combined impact of NeuroStar systems and lower margin Greenbrook clinic revenue.
• Critics highlight that the Greenbrook clinic business runs at a lower margin profile than the legacy NeuroStar device segment, and the reported move from a 66% gross margin in the prior year quarter to 52% in Q4 2025 fits that concern, even though efficiency efforts are aimed at offsetting this mix shift.
  • The bearish narrative points to the risk that if clinic revenue keeps growing faster than systems without enough cost efficiencies, longer term gross margin and EBITDA could stay under pressure.
  • At the same time, the consensus view notes that operational tools such as self check in kiosks and better intake processes are intended to create operating leverage, which would help margins if treatment volumes continue to build.

Bears who focus on clinic driven margin pressure may want to see how that case is built out across revenue mix, costs, and projected earnings in the dedicated narrative before deciding how much weight to give it. 🐻 Neuronetics Bear Case

Losses narrowing while still unprofitable

• On a trailing twelve month basis, Neuronetics reported revenue of US$149.2 million with a net loss of US$39.0 million and a basic EPS loss of US$0.59, compared with a trailing loss of US$43.7 million on US$74.9 million of revenue as of Q4 2024.
• Supporters argue that analysts expecting about 12.6% annual revenue growth over the next 3 years see this revenue base as a platform for future earnings, although the company is still forecast to remain unprofitable and currently carries a price to sales ratio of roughly 1x versus about 2.6x for peers and 2.8x for the wider US medical equipment industry.
  • The bullish narrative leans on operational programs like the Better Me Provider initiative and expanded adolescent coverage, which are tied to higher patient volumes and are intended to improve operating margins over time.
  • What stands out against that optimistic view is the history of losses increasing around 10.6% a year over the past 5 years and guidance that profitability is not expected in the next 3 years, so revenue growth has to work against a sizeable loss base.

Supporters who see narrowing losses and a low P/S multiple as attractive should understand how the optimistic case links clinic growth, margins, and long term earnings before treating these trends as a clear positive. 🐂 Neuronetics Bull Case

Low P/S multiple alongside revenue forecasts

• The stock trades on a trailing P/S of about 1x against analyst forecasts that revenue could grow around 12.1% a year, while the broader US medical equipment industry is cited at roughly 2.8x P/S and peers at about 2.6x.
• Consensus narrative commentators see this combination of a lower P/S multiple and double digit forecast revenue growth as a potential value angle, but they also flag that the share price has been volatile in recent months and that losses are projected to continue for at least 3 years, which means any perceived discount is closely tied to execution on revenue and margin plans.
  • Bears argue that heavier reliance on lower margin clinic and SPRAVATO buy and bill revenue, alongside higher operating expenses, could make it harder for that forecast growth to translate into stronger earnings.
  • By contrast, bulls point to broader acceptance of proactive mental health care, expanded insurance coverage, and programs that have lifted referral conversion as the key ingredients that could help justify a higher valuation if they feed through to sustained topline expansion.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Neuronetics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of risks and rewards feels finely balanced, take a closer look at the numbers now and decide where you stand by checking the 2 key rewards and 2 important warning signs.

See What Else Is Out There

Neuronetics is still loss making with margin pressure from lower margin clinic revenue and no profitability expected in the near term, leaving earnings risk on the table.

If you want ideas where pricing and earnings risk may be more favorable right now, check out the 72 resilient stocks with low risk scores that focuses on companies with more resilient profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.